Navigation Links
GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
Date:12/6/2008

let count to 36,000/microliters, with median platelet levels subsequently ranging from 52,000 to 91,000/microliters for the remainder of the study, meeting the study's primary endpoint of odds of responding (platelets 50,000 to 400,000/microliters) during the six month treatment period. Patients receiving PROMACTA were eight times more likely to achieve an overall response of increased platelet counts of 50,000 to 400,000/microliters than those taking placebo (Odds ratio = 8.2; 99 percent CI [3.59, 18.73]; p < 0.001). In comparison to the placebo group, significantly fewer patients treated with PROMACTA had any bleeding or clinically significant (WHO Grades 2-4; p < 0.001) bleeding throughout the trial and more patients in the PROMACTA group (59 percent) stopped or reduced their simultaneous ITP medications than in the placebo group (32 percent; p = 0.016). In addition, during the treatment phase of the study, fewer patients in the PROMACTA arm (19 percent) required rescue therapy compared with those in the placebo arm (40 percent, p = 0.001).

The overall incidence of adverse events was similar between the PROMACTA (87 percent) and placebo groups (92 percent), which were mostly mild to moderate in severity. Headache was the most common adverse event in both groups (greater than or equal to 30 percent). Two corticosteroid-associated adverse events (dyspepsia and peripheral edema) were significantly less likely to occur in the PROMACTA group compared to the placebo group; however, a higher incidence of hepatobiliary laboratory abnormalities were reported in patients taking PROMACTA (13 percent) compared with those in the placebo group (7 percent). These abnormalities were not predictive of serious, drug-induced liver injury. One death was reported in the placebo group. There were no clinical or laboratory symptoms suggestive of bone marrow fibrosis in patients taking PROMACTA.

Additional GSK Data Presented at
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
2. GEN Reports on the Trend Toward Predictive Toxicogenomics
3. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
4. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
7. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
8. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
10. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
11. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... ANGELES , SINGAPORE, and TOKYO , ... announced that it has appointed Roger Crystal , ... most recently served in the Global Business Development Product ... "Roger,s experience in developing business strategy and ... valuable as we continue to partner with biotechnology and ...
(Date:7/28/2014)... NEW PROVIDENCE, N.J. , July 28, 2014 /PRNewswire/ ... meet with Linde,s Healthcare division experts at the ... at McCormick Place in Chicago, Illinois ... nothing less than complete confidence in a reliable medical ... Segment manager. "Linde understands the importance of this critical ...
(Date:7/28/2014)... HILDEN , Germany ... 2014 , ... Begleitdiagnostikums, das auf Basis genomischer Daten aus Plasmaproben ... mit nicht-kleinzelligem Lungenkrebs eingesetzt werden kann  ... zugelassenem  therascreen   EGFR Kit und soll auf Rotor-Gene ...
Breaking Medicine Technology:ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development 2Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7
... 17, 2011 Stryker Corporation,s Orthopaedics Division and ... announced an agreement in which OrthoSensor will provide ... Stryker,s Triathlon Knee System. The OrthoSensor Knee Trial ... feedback to surgeons to optimize joint balance during ...
... 2011  ConvaTec, a world-leading developer and marketer of ... announced the appointments of Charles Cerminara and James Moran ... been appointed Vice President and General Manager, Greater China, ... the growth of the Chinese market and to leverage ...
Cached Medicine Technology:Stryker Orthopaedics Enters into Agreement with OrthoSensor for Intelligent Surgical Platform 2Stryker Orthopaedics Enters into Agreement with OrthoSensor for Intelligent Surgical Platform 3ConvaTec Announces Asia-Pacific Leadership Appointments 2
(Date:7/28/2014)... HealthDay Reporter MONDAY, July 28, 2014 (HealthDay ... are more likely to get a pacemaker than people without ... of more than 16,000 people found that those with dementia ... pacemaker than those without the memory-robbing condition. What ... are so much more likely to be treated with a ...
(Date:7/28/2014)... Michigan (PRWEB) July 28, 2014 The ... Drs. Harris, Birkhill, Wang, Songe and Associates, PC that ... and countless tomorrows to come. , The HBWS ... responsible for more than $2.5 million in donations. Through ... title sponsors for the Oakwood Women’s Healthcare Classic for ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July 28, 2014 ... apnea in children, but a new study confirms that the ... already overweight. The researchers said that,s a concern, because ... problems -- including, ironically, sleep apnea. But they,re not advising ... said, doctors and parents should be aware that a healthy ...
(Date:7/28/2014)... 28, 2014 Lourdes Health System has ... and reduced wait times for veterans needing medical care. ... in the state—and the only one in Camden, Burlington ... Community Care program (PC3). PC3 gives veterans access to ... cannot provide services due to lack of available specialists, ...
(Date:7/28/2014)... 28, 2014 The American ... of professionals engaged in the field of organ ... Transplantation and Immunology Research Network (TIRN), a ... research. As modern organ transplantation continues to diversify, ... could provide more opportunities for physicians, scientists and ...
Breaking Medicine News(10 mins):Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 2Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 3Health News:Lourdes Expands Military Partnership with Veterans 2Health News:Lourdes Expands Military Partnership with Veterans 3Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3
... Neb., March 1 Nelnet, Inc. (NYSE: ... of its 2008 year-end results,as the company,s independent external ... derivative portfolio, which is excluded from base,net income. The ... market open on March 2, 2009. Depending on the ...
... the security alarms of the immune system. After sensing ... alarm to white blood cells or tell them to ... , Researchers at the Emory Vaccine Center and Yerkes ... can respond to the same compound, through two different ...
... office in Tokyo. , ... (PRWEB) March 1, 2009 ... services firm, which provides clinical research support services to pharmaceutical, biotechnology, ... Tokyo, Japan., , ,To meet the growing needs and serve its ...
... Ill. A study in the March 1 issue of ... intrinsic sleep problem specific to attention-deficit/hyperactivity disorder (ADHD) and supports ... deprived and have abnormal REM sleep. , Results ... that is significantly shorter than that of controls. Children ...
... Brian Schweitzer (Chair of the Democratic Governors Association) and ... today applauded President Obama,s reported selection of former DGA ... Human Services. "Our health care system is broken, and ... the effort to fix it," Governor Schweitzer said. "In ...
... for rare, orphan and neglected diseases, launches iWish, which allows people ... these diseases through and image. In addition, people are invited to ... creative solutions for a rare disease or for the community in ... ...
Cached Medicine News:Health News:Vitamin A signals offer clues to treating autoimmunity 2Health News:Underlying sleep problem linked to attention-deficit/hyperactivity disorder in children 2Health News:CheckOrphan Launches iWish to Commemorate Rare Disease Day 2Health News:CheckOrphan Launches iWish to Commemorate Rare Disease Day 3
... cannula with 30 gauge, 4.76 mm tip is ... Cannula is attached to a luer lock high ... inch long), for use with high viscosity substances. ... using visco elastic materials. Flattened, angled tip of ...
20 gauge x 25 mm cannula with 30 degree x 5 mm tip. 30 gauge cannula extends into hub 2 mm from end of hub. 10 per box....
Developed for oculoplastic procedures for corneal and scleral protection. Dimensions enable protector to rest on the sclera and not on the cornea. Easily removed with Bishop-Harmon Forceps. Individua...
The moist air humidifying chamber is designed for the infusion of humidified air during phakic fluid air exchange. Sterile single-use. 10 per box. Most popular size or model....
Medicine Products: